FIT1 Antibody

What is FIT1 protein and why are antibodies against it important?

FIT1, more commonly referenced in scientific literature as IL1RL1 (interleukin 1 receptor like 1), is a receptor protein for interleukin-33 (IL-33). This protein requires association with the coreceptor IL1RAP for proper signaling. It consists of 556 amino acid residues with a molecular mass of approximately 63.4 kilodaltons. FIT1 is localized in the cell membrane and can also be secreted . Antibodies against FIT1 are crucial for studying the IL-33/ST2 signaling pathway, which plays significant roles in inflammatory responses, immune regulation, and various pathological conditions. These antibodies enable detection, quantification, and functional analysis of FIT1/IL1RL1 in experimental systems .

What are the main applications for FIT1 antibodies in research?

FIT1 antibodies are versatile research tools with multiple applications:

• Western blotting for protein detection and semi-quantitative analysis

• ELISA for quantitative measurement of FIT1 levels in biological samples

• Immunohistochemistry for tissue localization studies

• Flow cytometry for cell surface expression analysis

• Immunoprecipitation for protein-protein interaction studies

• Functional blocking experiments to investigate IL-33/ST2 signaling

Each application requires specific antibody characteristics such as epitope specificity, affinity, and format (monoclonal vs. polyclonal).

How should researchers determine appropriate antibody concentrations for different applications?

Determining optimal antibody concentration is critical for experimental success and requires systematic titration:

The optimization should include validation with appropriate controls such as tissue samples with known FIT1 expression profiles. When optimizing, researchers should target signal-to-noise ratios that provide clear distinction between specific and background signals .

How can researchers validate the specificity of FIT1 antibodies?

Validating FIT1 antibody specificity requires multiple approaches:

• Genetic knockout validation: Compare antibody binding in wild-type versus FIT1/IL1RL1 knockout cell lines or tissues

• Peptide competition assays: Pre-incubate antibody with purified FIT1 protein or immunizing peptide

• Multiple antibody validation: Use multiple antibodies targeting different epitopes

• Mass spectrometry: Confirm identity of immunoprecipitated proteins

• RNA expression correlation: Compare protein detection with corresponding mRNA expression data

A robust validation strategy includes at least three independent methods to confirm specificity before proceeding with experimental applications.

How can researchers optimize FIT1 antibody performance in tissue-specific studies?

FIT1/IL1RL1 shows differential expression across tissues, with high expression reported in kidney, lung, placenta, stomach, skeletal muscle, colon, and small intestine . Optimizing antibody performance for tissue-specific studies requires:

• Selection of antibodies validated in the tissue of interest

• Adjustment of tissue preparation protocols based on FIT1 expression levels

• Implementation of tissue-specific antigen retrieval methods

• Consideration of potential cross-reactivity with tissue-specific proteins

• Use of appropriate blocking reagents to minimize background in specific tissues

Researchers should conduct preliminary experiments with multiple antibody clones to identify the most suitable candidate for their specific tissue of interest.

What strategies can address challenges in detecting low levels of FIT1 expression?

For tissues or cells with low FIT1 expression:

• Signal amplification: Use tyramide signal amplification (TSA) or polymer-based detection systems

• Enrichment: Perform subcellular fractionation to concentrate membrane-bound FIT1

• Higher sensitivity antibody formats: Consider biotin-conjugated antibodies with streptavidin detection

• Enhanced imaging: Use more sensitive microscopy techniques, such as confocal or super-resolution microscopy

• Quantitative PCR correlation: Validate protein detection results with corresponding mRNA quantification

These approaches should be systematically evaluated to determine which combination provides optimal detection sensitivity for the specific experimental context.

What are recommended protocols for using FIT1 antibodies in Western blotting?

Western blotting with FIT1 antibodies requires careful optimization:

• Sample preparation:

  • Include protease inhibitors to prevent degradation

  • For membrane-bound FIT1, use membrane-compatible lysis buffers

  • For secreted forms, concentrate culture supernatants

• Electrophoresis conditions:

  • Use 8-10% SDS-PAGE gels for optimal resolution of the 63.4 kDa protein

  • Include positive control lysates from tissues known to express FIT1

• Transfer and detection:

  • Semi-dry transfer at 15V for 30-45 minutes or wet transfer at 30V overnight

  • Block with 5% non-fat milk or BSA in TBST

  • Incubate with primary antibody (typically 1:500-1:2000 dilution)

  • Visualize using appropriate secondary antibody and detection system

• Validation:

  • Confirm band size at approximately 63.4 kDa

  • Include controls for specificity (e.g., peptide competition or knockdown samples)

How should researchers troubleshoot non-specific binding with FIT1 antibodies?

Non-specific binding is a common challenge that can be addressed systematically:

• Increase blocking stringency:

  • Extend blocking time to 2 hours or overnight

  • Try alternative blocking agents (BSA, casein, commercial blockers)

  • Add 0.1-0.5% Tween-20 to reduce hydrophobic interactions

• Optimize antibody conditions:

  • Further dilute primary antibody

  • Reduce incubation time or temperature

  • Add 0.1-0.3M NaCl to reduce ionic interactions

• Sample preparation adjustments:

  • Pre-clear lysates with Protein A/G beads

  • Pre-absorb antibody with proteins from negative control sources

• Control experiments:

  • Include isotype controls

  • Perform secondary-only controls

  • Use tissue or cells known to be negative for FIT1 expression

Systematic documentation of each optimization step helps identify the most effective approach for specific experimental conditions.

How do FIT1 antibodies contribute to understanding IL-33 signaling pathways?

FIT1/IL1RL1 antibodies have been instrumental in elucidating IL-33 signaling mechanisms. Research demonstrates that FIT1 serves as the primary receptor for IL-33, requiring association with IL1RAP coreceptor for signal transduction . Antibodies targeting different epitopes of FIT1 have helped:

• Map the binding interface between IL-33 and FIT1

• Identify conformational changes upon ligand binding

• Visualize receptor clustering and internalization kinetics

• Quantify receptor expression levels in different cell types

• Assess activation of downstream signaling components

These studies have established FIT1/IL1RL1 as a critical component in inflammatory responses, allergy, and tissue homeostasis mechanisms.

What lessons from bispecific antibody development apply to FIT1 research?

The development of bispecific antibodies like FIT-1 (a Zika virus-targeting bispecific antibody) provides valuable insights for FIT1/IL1RL1 research :

• Epitope targeting strategy: FIT-1 combines two antibodies (ZKA190 and ZKA185) targeting different epitopes to prevent viral escape. Similarly, researchers can design experiments using multiple FIT1 antibodies targeting distinct epitopes for more comprehensive protein characterization.

• Structural insights: The structural analysis methods used with FIT-1, including NMR and cryo-electron microscopy, demonstrate how antibody binding can alter target protein conformation . These techniques can be applied to understand IL-33/FIT1 interactions.

• Escape mutation prevention: FIT-1's design prevents viral escape mutations . This principle can inform the development of therapeutic antibodies targeting FIT1 in disease contexts where protein variants might emerge.

• Functional restoration: Similar to how FIT-1 restores protection against viral infection, researchers can explore how different FIT1 antibodies might modulate IL-33 signaling pathway activity.

How can single-cell techniques enhance FIT1 research using antibodies?

Single-cell analysis techniques offer new opportunities for FIT1/IL1RL1 research:

• Single-cell proteomics can reveal cell-to-cell variability in FIT1 expression levels and post-translational modifications

• Mass cytometry (CyTOF) using FIT1 antibodies enables high-dimensional analysis of FIT1 expression in complex cell populations

• Imaging mass cytometry can map spatial distribution of FIT1 in tissues with subcellular resolution

• Proximity ligation assays can detect FIT1 interactions with IL-33 or other binding partners at the single-molecule level

• Single-cell RNA-seq combined with protein detection can correlate FIT1 mRNA and protein levels

These approaches allow researchers to move beyond population-level analyses to understand heterogeneity in FIT1 expression and function at the individual cell level.

What considerations are important when developing functional blocking antibodies against FIT1?

Developing functional blocking antibodies against FIT1/IL1RL1 requires:

• Epitope mapping to target regions critical for IL-33 binding or signal transduction

• Affinity optimization to ensure effective competition with the natural ligand

• Format selection (Fab, F(ab')2, or whole IgG) based on experimental requirements

• Fc engineering to prevent unwanted effector functions

• Validation in multiple functional assays:

  • Cell-based reporter systems

  • Phosphorylation assays for downstream signaling

  • Cytokine production measurements

  • In vivo models of IL-33-dependent responses

Researchers should also consider potential differences between blocking membrane-bound versus soluble forms of FIT1, as these may have distinct biological functions.

How can FIT1 antibodies be applied in immunotherapy research?

FIT1/IL1RL1 antibodies have potential applications in immunotherapy research:

• As therapeutic candidates for diseases involving IL-33/ST2 signaling, including asthma, atopic dermatitis, and certain inflammatory conditions

• For patient stratification based on FIT1 expression profiles

• In monitoring treatment responses through measurement of soluble FIT1 levels

• For developing antibody-drug conjugates targeting FIT1-expressing cells

• In engineering CAR-T cells using FIT1-specific single-chain variable fragments

Learning from bispecific antibody designs like FIT-1, researchers can explore dual-targeting approaches combining FIT1 with other relevant immune targets .

What approaches can distinguish between membrane-bound and soluble forms of FIT1?

Distinguishing between membrane-bound and soluble FIT1 requires specialized approaches:

• Antibody selection:

  • Antibodies targeting the extracellular domain detect both forms

  • Antibodies specific to membrane-proximal regions may preferentially detect membrane-bound forms

• Sample preparation:

  • Cellular fractionation to separate membrane and cytosolic/secreted compartments

  • Ultracentrifugation to isolate membrane vesicles containing FIT1

• Analytical methods:

  • Flow cytometry for cell surface (membrane-bound) FIT1

  • ELISA for soluble FIT1 in biological fluids

  • Immunoprecipitation combined with Western blotting using antibodies against different FIT1 domains

• Imaging approaches:

  • Confocal microscopy with membrane co-staining

  • Live-cell imaging to track FIT1 localization and dynamics

These approaches provide complementary information about the different forms of FIT1 and their potential distinct biological functions.